Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 19.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.0%)
  • Dividend yield for the last twelve months 3.3%
  • Free cash flow yield -2.5% (LTM)
  • Share price is 47.9% higher than minimum and 9.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (38.0x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+3.7%)195.93
year average price 188.77  


year start price 189.29 2024-08-02

min close price 164.99 2024-11-15

max close price 216.66 2025-03-10

current price 195.93 2025-08-01
Common stocks: 1 768 480 508

Dividend Yield:  3.3%
FCF Yield LTM: -2.5%
EV / LTM EBITDA: 38.0x
EV / EBITDA annualized: 25.5x
Last revenue growth (y/y):  +8.4%
Last growth of EBITDA (y/y):  +31.3%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -20.4%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 346 498
Net Debt ($m): 64 755
EV (Enterprise Value): 411 253
EBITDA LTM ($m): 10 815
EV / LTM EBITDA: 38.0x
Price to Book: 55.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-31zacks.com

AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View

2025-07-31zacks.com

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

2025-07-31prnewswire.com

AbbVie Reports Second-Quarter 2025 Financial Results

2025-07-30prnewswire.com

AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

2025-07-30fool.com

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever

2025-07-29reuters.com

Lilly's cancer drug more effective than AbbVie's in head-to-head study

2025-07-28zacks.com

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

2025-07-26fool.com

The Smartest Dividend Stocks to Buy With $350 Right Now

2025-07-22seekingalpha.com

Best Dividend Kings: July 2025

2025-07-19fool.com

All It Takes Is $2,000 Invested in Each of These High Dividend Stocks to Help Generate Over $280 in Passive Income Per Year
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data